AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01009918
Drug: lisinopril
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01094925
Drug: Gabapentin 300mg
RxNorm normalized name: GABAPENTIN 300MG CAP
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral dose of 300mg gabapentin
Trial: NCT01094925
Drug: Gabapentin 600mg
RxNorm normalized name: GABAPENTIN 600MG TAB
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral dose of 600mg gabapentin
Trial: NCT01371526
Drug: depot tetracosactide
RxNorm normalized name: tetracosactide
DrugBank: Tetracosactide (DB01284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1mg, 3x weekly by sc injection
Trial: NCT04771026
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pre-operatively nebuliser dexamethasone 8mg prior to induction of anesthesia
Trial: NCT00162526
Drug: Tocopherol
RxNorm normalized name: tocopherol
DrugBank: Tocopherol (DB11251)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03588611
Drug: Bivalirudin
RxNorm normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.75mg/kg+ 1.75 mg/kg▪h for the duration of PCI;
Trial: NCT03588611
Drug: Bivalirudin
RxNorm normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.6mg/kg+ 1.75 mg/kg▪h for the duration of PCI;
Trial: NCT01934933
Drug: celebrex
RxNorm normalized name: Celebrex
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01934933
Drug: Enbrel
RxNorm normalized name: Enbrel
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02256215
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00511849
Drug: carboplatin + SU011248 (sunitinib) + paclitaxel
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC of 6 mg\*min/mL administered as a 30-minute infusion, every 21 days for 4 cycles or until progression/unacceptable toxicity. 25 mg, 37.5 mg, or 50 mg (depending on the dose level assigned) orally taken every day or for 2 weeks and 1 week off without for 4 cycles or until progression/unacceptable toxicity. 175 mg/m2, 200 mg/m2, or 225 mg/m2 (depending on the dose level assigned), administered as a 3-hour infusion every 21 days for 4 cycles or until progression/unacceptable toxicity.
Trial: NCT03605433
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban 2.5 mg or Rivaroxaban 20 mg or no oral anticoagulation
Trial: NCT02246127
Drug: Drug: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10mg/daily, oral. Number of Cycles: until progression or unacceptable toxicity develops.
Trial: NCT03120962
Drug: Oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone 20mg/day, for 4 weeks
Trial: NCT03120962
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 900mg/day, titrated up to max tolerated dose or 1800mg/day, for 4-12 weeks
Trial: NCT03120962
Drug: Famciclovir
RxNorm normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Famciclovir 500mg three-times daily for 7 days
Trial: NCT01280266
Drug: Udenafil or Amlodipine
RxNorm normalized name: ORE-1001
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 10mg daily then Udenafil 100 mg daily OR Udenafil 100 mg daily then Amlodipine 10mg daily
Trial: NCT01929213
Drug: Udenafil
RxNorm normalized name: udenafil
DrugBank: Udenafil (DB06267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Udenafil is administered
Trial: NCT00796250
Drug: AZA
RxNorm normalized name: Baza
DrugBank: Clobazam (DB00349)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in this group were treated with AZA, infliximab, and placebo prednisolone. All patients were treated with AZA, by oral use, with a 2 mgkg dose a day until the end of the study (30 weeks).
Trial: NCT00796250
Drug: AZA
RxNorm normalized name: Baza
DrugBank: Clobazam (DB00349)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in this group were treated with AZA, prednisolone, and placebo infliximab. All patients were treated with AZA, by oral use, with a 2 mgkg dose a day until the end of the study (30 weeks).
Trial: NCT00238433
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3.2mg/kg/day for 3 days starting on day -8. Each dose of intravenous busulfan will be mixed in a concentration of 0.54 mg/ml of 0.9% saline and infused over 3 hours.
Trial: NCT00238433
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg/m2/day/iv, infused over 30 minutes on days -5 and -4. The reconstituted melphalan is diluted in 250cc normal saline to a concentration not greater than 0.4 mg/ml.
Trial: NCT00238433
Drug: thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 250 mg/m2/day/iv on days -3 and -2
Trial: NCT01929213
Drug: Bosentan
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bosentan is administered
Trial: NCT01929213
Drug: Udenafil/Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Udenafil and Bosentan are administered
Trial: NCT01373918
Drug: Intralipid
RxNorm normalized name: Intralipid
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject will receive 1 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.
Trial: NCT04042155
Drug: dabigatran, rivaroxaban, apixaban or edoxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Record of all serious complications associated with any of the drugs and the clinical changes that occurred during prospective follow-up.
Trial: NCT01373918
Drug: Intralipid
RxNorm normalized name: Intralipid
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject will receive 3 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.
Trial: NCT00649857
Drug: Cetirizine HCl Tablets 10 mg
RxNorm normalized name: cetirizine hydrochloride Chewable Tablet
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg, single dose fed
Trial: NCT01136863
Drug: Felodipine
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00192595
Drug: Tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00192595
Drug: Zidovudine (AZT), lamivudine (LAM), efavirenz (EFV)
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02194556
Drug: Sequential and maintenance icotinib
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
DrugBank: Icotinib (DB11737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are administered with sequential and maintenance icotinib plus chemotherapy. Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1, sequential icotinib 125 mg is administered orally three times per day at d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive maintenance icotinib until disease progression or intolerable toxicity.
Trial: NCT00526643
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1200 mg/m2 intravenous infusion on days 1 and 8, every 3 weeks for a maximum of 4 cycles
Trial: NCT00526643
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cisplatin 60 mg/m2 on day 1 for 4 cycles
Trial: NCT00034255
Drug: INGAP Peptide
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03496519
Drug: Dose Escalation of Durvalumab and Trabectedin
DrugBank: Trabectedin (DB05109)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: There will be a fixed dosage of Durvalumab, 1125mg, given intravenously over 60 minutes on Day 2 every 21 days. There will be an increase in Trabectedin for each cohort, given through intravenous infusion over a 24 hour period on Day 1 every 21 days as an outpatient.~* Cohort -1: Durvalumab 1125mg with Trabectedin 0.5mg/m2~* Cohort 1: Durvalumab 1125mg with Trabectedin 0.75mg/m2~* Cohort 2: Durvalumab 1125mg with Trabectedin 1.0mg/m2~* Cohort 3: Durvalumab 1125mg with Trabectedin 1.2mg/m2~* Cohort 4: Durvalumab 1125mg with Trabectedin 1.5mg/m2
Trial: NCT03496519
Drug: Dose Expansion of Durvalumab and Trabectedin
DrugBank: Trabectedin (DB05109)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: There will be a fixed dosage of Durvalumab, 1125mg, given intravenously over 60 minutes on Day 2 every 21 days. There will be a fixed dosage of Trabectedin for each cohort, whatever was determined to be the safest dose during the Dose Escalation Phase, and it will be given through intravenous infusion over a 24 hour period on Day 1 every 21 days as an outpatient.
Trial: NCT02194556
Drug: Maintenance icotinib
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
DrugBank: Icotinib (DB11737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive maintenance icotinib (125 mg three times per day) until disease progression or intolerable toxicity.
Trial: NCT00961441
Drug: Keppra XR
RxNorm normalized name: Keppra XR
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Keppra XR 500 mg tablets and Keppra XR 750 mg tablets~Dosage: Keppra XR 1000-3000 mg/day taken once daily. Duration: 4-7 days
Trial: NCT01445925
Drug: Pharmacological Substrate modification
RxNorm normalized name: BISMUTH SUBCITRATE
DrugBank: Fica (DB03384)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: at least 6 weeks therapy with oral amiodarone prior to the ablation procedure and 6 weeks post.
Trial: NCT01911728
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01911728
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01911728
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01911728
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral
Trial: NCT01451879
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Clinically prescribed immune modulation regimen dosage determined by local medical provider.
Trial: NCT01451879
Drug: Miglustat
RxNorm normalized name: Miglustat
DrugBank: Miglustat (DB00419)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clinically prescribed immune modulation regimen dosage determined by local medical provider.
Trial: NCT03616184
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with sclerotic chronic graft-versus-host disease (GVHD) will receive oral ruxolitinib at a dose of 10 mg twice daily. Doses may not exceed 10 mg twice daily. Ruxolitinib will be continued for 6 months. Patients who continue to have stable disease, mixed responses or partial/complete responses at the end of 6 months may continue the drug for a total of 12 months.
Trial: NCT03386201
Drug: Intravenous Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue fluorescence cholangiography during laparoscopic cholecystectomy
Trial: NCT02533401
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine will be administered IV at 25 mg/m\^2/day on Day 2-4 of Cycle 1 and then on Day 1-3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
Trial: NCT02533401
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab will be administered IV at 375 mg/m\^2 on Day 1 of Cycle 1 and then at 500 mg/m\^2 on Day 1 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
Trial: NCT00799760
Drug: oseltamivir + zanamivir
RxNorm normalized name: Zanamivir
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral oseltamivir 75mg twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 days
Trial: NCT00107250
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC 6; IV; 30 minutes; Every 21 days for a maximum of 6-8 cycles
Trial: NCT00107250
Drug: cediranib maleate
RxNorm normalized name: maleate
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given daily; orally with approximately 240 ml of water whilst in an upright position
Trial: NCT00107250
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200mg/m2; IV; 3 hours; Every 21 days for a maximum of 6-8 cycles
Trial: NCT00799760
Drug: oseltamivir + zanamivir's placebo
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral oseltamivir 75mg twice daily+ placebo inhaled by mouth twice daily during 5 day
Trial: NCT00799760
Drug: oseltamivir's placebo + zanamivir
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral placebo twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 day
Trial: NCT00291499
Drug: Chondroitin 4&6 sulfate (Condrosulf)
DrugBank: Chondroitin sulfate (DB09301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg/day for 6 months
Trial: NCT02483897
Drug: Tetracaine 0.5% ophthalmic drops
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.8 mls. drops provided to be used hourly p.r.n. for pain control
Trial: NCT02483897
Drug: Normal Saline placebo drops
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mls. drops provided to be used hourly p.r.n. for pain control
Trial: NCT01362439
Drug: Paliperidone ER
RxNorm normalized name: Paliperidone ER
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will be administered paliperidone extended release (ER) tablets orally (taken by mouth; to be swallowed) once daily in the dose range of 3 to 12 milligram (mg) for 13 weeks. Dose will be increased or decreased as per Investigator's discretion.
Trial: NCT00311038
Drug: ONO-1101
RxNorm normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04834791
Drug: Letrozole 2.5mg
RxNorm normalized name: LETROZOLE 2.5MG TAB
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: These patients were treated with letrozole (Femara®, Novartis New York, NY, USA) in a dose 2.5 mg (one tablet daily) orally began on the 3rd day to the 7th day of the cycle. If ovulation is not achieved dose is increased by 2.5 mg in next cycle till 3 cycles
Trial: NCT04834791
Drug: Gonadotropin
RxNorm normalized name: Gonadotropin
DrugBank: Choriogonadotropin alfa (DB00097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: These patients were given urofollitropin (fostimon ®, IBSA, Lugano, Switzerland) in a dose of 75 IU/mL I.M from day 3rd to day 7th of the cycle beginning by one ampoule per day and the dose had been modulated according to response.
Trial: NCT01463956
Drug: Boceprevir
RxNorm normalized name: Boceprevir
DrugBank: Boceprevir (DB08873)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Boceprevir 200 mg capsules at 2400mg/day (800mg 3 times a day) from week 4 until week 48 or until liver transplant (can be performed from week 16)
Trial: NCT01463956
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin: capsules 200 mg (weight-based daily dose: \<65kg, 800 mg; 65-80kg, 1000mg; 81-105kg: 1200mg; \>105kg: 1400mg), from day 0 until week 48 or until liver transplantation or, Ribavirin: Tablet Oral, weight-based dose, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over75 kg, once daily, from day 0 until week 48 or until liver transplantation
Trial: NCT03741101
Drug: Trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: treatment
Trial: NCT02202746
Drug: Lucitanib
RxNorm normalized name: Lucitanib
DrugBank: Lucitanib (DB11845)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lucitanib is a potent, orally available selective inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors (FGFR1-3), vascular endothelial growth factor receptors (VEGFR1-3), and platelet-derived growth factor receptors alpha and beta (PDGFR alpha and beta)
Trial: NCT04252742
Drug: Erenumab
RxNorm normalized name: ERENUMAB
DrugBank: Erenumab (DB14039)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 140 mg, 2 consecutive injections of 70 mg
Trial: NCT00387582
Drug: Ranibizumab (Lucentis)
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lucentis 0.5 mg monthly for the first three months and then per protocol for the duration of the trial.
Trial: NCT00464802
Drug: MOA-728
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00831506
Drug: digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: digoxin once daily (0.125 mg QD) plus placebo three times daily (TID), 8 hours apart for 14 days.
Trial: NCT00831506
Drug: digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: digoxin once daily (0.125 mg QD) for 14 days.
Trial: NCT00831506
Drug: dimebon
RxNorm normalized name: Dimebon
DrugBank: Latrepirdine (DB11725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimebon three times a day, 8 hours apart for 14 days (10 mg TID on Days 1-7 and 20 mg TID on Days 8-14).
Trial: NCT01011621
Drug: 0.1% betamethasone valerate cream
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Small amount applied over the lesion twice a day for 14 days.
Trial: NCT03905330
Drug: Maralixibat
RxNorm normalized name: Maralixibat
DrugBank: Maralixibat (DB16226)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maralixibat oral solution (up to 600 mcg/kg) orally twice daily for 26 weeks.
Trial: NCT01528384
Drug: ADI-PEG 20
RxNorm normalized name: ADI-PEG 20
DrugBank: Pegargiminase (DB06592)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5, 9 and 18 mg/m2 dosage weekly dosing intramuscular until progressive disease
Trial: NCT01717066
Drug: the ginsenoside Rg3
RxNorm normalized name: ginsenoside
DrugBank: Ginsenoside Rg3 (DB19257)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02474914
Drug: Octreotide
RxNorm normalized name: Octreotide
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Octreotide will be given after PD
Trial: NCT02652741
Drug: Enalapril Orodispersible Minitablet
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8-weeks treatment, open, uncontrolled, PK/PD, acceptability and palatability assessments and safety assessments after Enalapril intake in form of 0.25 mg or 1 mg ODMTs
Trial: NCT02782169
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin 300 mg capsule (over encapsulated to maintain blinding)
Trial: NCT02268448
Drug: Clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01156948
Drug: misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400ug vaginally the day before surgery
Trial: NCT01156948
Drug: oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400ug misoprostol orally the day before the surgery
Trial: NCT02268448
Drug: Naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02085148
Drug: Regorafenib (BAY73-4506)
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib will be given orally once a day, across cycles of 21 days each. During each cycle regorafenib is taken for 2 weeks followed by one week off the drug. Doses of the study drug used in this study are age-dependent and the children's dose will been adjusted based on the age and the body surface area and given either as tablets or granulate.
Trial: NCT02085148
Drug: Vincristine (Cellcristin®)
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vincristine will be given at a dose of 1.5 mg/m2 (0.05 mg/kg for subjects ≤ 10 kg, maximum 2.0 mg) on Day 1 and Day 8 in 21-day cycles.
Trial: NCT02085148
Drug: Irinotecan (Irinotecan Cell pharm®)
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan will be administered at a starting dose of 50 mg/m2/day from Day 1 to Day 5, in 21 day cycles.